Tìm theo
Norfloxacin
Các tên gọi khác (7 ) :
  • 1-Ethyl-6-fluor-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-chinolincarbonsaeure
  • 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid
  • 1,4-Dihydro-1-ethyl-6-fluoro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid
  • NFLX
  • Norfloxacine
  • Norfloxacino
  • Norfloxacinum
Thuốc trị ký sinh trùng, chống nhiễm khuẩn
Thuốc Gốc
Small Molecule
CAS: 70458-96-7
ATC: S01AE02, J01MA06
ĐG : Amerisource Health Services Corp. , http://www.amerisourcebergen.com
CTHH: C16H18FN3O3
PTK: 319.3308
A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase. [PubChem]
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C16H18FN3O3
Phân tử khối
319.3308
Monoisotopic mass
319.133219662
InChI
InChI=1S/C16H18FN3O3/c1-2-19-9-11(16(22)23)15(21)10-7-12(17)14(8-13(10)19)20-5-3-18-4-6-20/h7-9,18H,2-6H2,1H3,(H,22,23)
InChI Key
InChIKey=OGJPXUAPXNRGGI-UHFFFAOYSA-N
IUPAC Name
1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid
Traditional IUPAC Name
norfloxacin
SMILES
CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(C=C12)N1CCNCC1
Độ tan chảy
227-228 °C
Độ hòa tan
1.78E+005 mg/L
logP
-1.03
logS
-2.5
pKa (strongest acidic)
5.77
pKa (Strongest Basic)
8.68
PSA
72.88 Å2
Refractivity
85.48 m3·mol-1
Polarizability
32.26 Å3
Rotatable Bond Count
3
H Bond Acceptor Count
6
H Bond Donor Count
2
Physiological Charge
0
Number of Rings
3
Bioavailability
1
Rule of Five
true
Dược Lực Học : Norfloxacin is a quinolone/fluoroquinolone antibiotic. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase, which allows the untwisting required to replicate one DNA double helix into two. Notably the drug has 100 times higher affinity for bacterial DNA gyrase than for mammalian.
Cơ Chế Tác Dụng : A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase. [PubChem] The bactericidal action of Norfloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair, and recombination. Norfloxacin is a broad-spectrum antibiotic that is active against both gram-positive and gram-negative bacterias. The fluorine atom at the 6 position increases potency against gram-negative organisms, and the piperazine moiety at the 7 position is responsible for anti-pseudomonal activity
Dược Động Học :
▧ Absorption :
Rapid
▧ Protein binding :
10 and 15% (Serum protein binding)
▧ Metabolism :
Via liver and kidney
▧ Route of Elimination :
Norfloxacin is eliminated through metabolism, biliary excretion, and renal excretion. Renal excretion occurs by both glomerular filtration and tubular secretion as evidenced by the high rate of renal clearance (approximately 275 mL/min).
▧ Half Life :
3-4 hours
Chỉ Định : For the treatment of urinary tract infection
Tương Tác Thuốc :
  • Acenocoumarol The quinolone antibiotic, norfloxacin, may increase the anticoagulant effect of acenocoumarol.
  • Aluminium Formation of non-absorbable complexes
  • Aminophylline Norfloxacin may increase the effect of aminophylline.
  • Anisindione The quinolone antibiotic, norfloxacin, may increase the anticoagulant effect of anisindione.
  • Artemether Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Caffeine Norfloxacin may increase the effect and toxicity of caffeine.
  • Calcium Formation of non-absorbable complexes
  • Calcium Acetate Calcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as norfloxacin. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements.
  • Clozapine Ciprofloxacin may increase clozapine serum levels
  • Cyclosporine Norfloxacin may increase the effect and toxicity of cyclosporine.
  • Dicoumarol The quinolone antibiotic, norfloxacin, may increase the anticoagulant effect of dicumarol.
  • Dyphylline Norfloxacin may increase the effect of dyphylline.
  • Foscarnet Increased risk of convulsions
  • Iron Formation of non-absorbable complexes
  • Iron Dextran Formation of non-absorbable complexes
  • Lumefantrine Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Magnesium Formation of non-absorbable complexes
  • Magnesium oxide Formation of non-absorbable complexes
  • Oxtriphylline Norfloxacin may increase the effect of oxtriphylline.
  • Sucralfate Formation of non-absorbable complexes
  • Tacrine The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by strong CYP1A2 inhibitors such as Norfloxacin. Consider modifying therapy to avoid Tacrine toxicity. Monitor the efficacy and toxicity of Tacrine if Norfloxacin is initiated, discontinued or if the dose is changed.
  • Tacrolimus Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
  • Tamsulosin Norfloxacin, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Norfloxacin is initiated, discontinued, or dose changed.
  • Theophylline Norfloxacin may increase the effect of theophylline.
  • Thiothixene May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. The strong CYP1A2 inhibitor, Norfloxacin, may also decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or dose changed. Thorough risk:benefit assessment is required prior to co-administration.
  • Tizanidine Norfloxacin may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.
  • Tolterodine Norfloxacin may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
  • Toremifene Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
  • Tramadol Norfloxacin may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
  • Trazodone The CYP3A4 inhibitor, Norfloxacin, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Norfloxacin is initiated, discontinued or dose changed.
  • Trimipramine Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
  • Voriconazole Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
  • Vorinostat Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
  • Warfarin The quinolone antibiotic, norfloxacin, may increase the anticoagulant effect of warfarin.
  • Zinc Formation of non-absorbable complexes
  • Ziprasidone Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
  • Zuclopenthixol Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Liều Lượng & Cách Dùng : Tablet - Oral
Dữ Kiện Thương Mại
Giá thị trường
Nhà Sản Xuất
  • Công ty :
    Sản phẩm biệt dược : Chibroxin
  • Công ty :
    Sản phẩm biệt dược : Noroxin
Đóng gói
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB01059
PubChem Compound
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=4539
PubChem Substance
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46508634
KEGG Compound
http://www.genome.jp/dbget-bin/www_bget?cpd:C06687
KEGG Drug
http://www.genome.jp/dbget-bin/www_bget?drug:D00210
ChemSpider
http://www.chemspider.com/Chemical-Structure.4380.html
BindingDB
http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50045000
National Drug Code Directory
http://www.hipaaspace.com/Medical_Billing/Coding/National.Drug.Codes/PDF/0006-0705-68
PharmGKB
http://www.pharmgkb.org/drug/PA450654
Wikipedia
http://en.wikipedia.org/wiki/Norfloxacin
RxList
http://www.rxlist.com/cgi/generic3/norfloxacin.htm
PDRhealth
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/nor1302.shtml
Drugs.com
http://www.drugs.com/mtm/norfloxacin-ophthalmic.html
... loading
... loading